Table 3 The relationships between the myxoid stroma and clinicopathological characteristics analyzed using χ2 and Fisher’s exact tests
From: Myxoid stroma is associated with postoperative relapse in patients with stage II colon cancer
| Â | Myxoid | Â | Â | Myxoid | Â | ||
|---|---|---|---|---|---|---|---|
Absent (%) | Present (%) | p value | Â | Absent (%) | Present (%) | p value | |
Gender) | Â | Â | Â | Lymphatic invasion | Â | Â | Â |
 Female | 62 (45) | 13 (41) | 0.7 |  Absent | 87 (64) | 17 (53) | 0.36 |
 Male | 75 (55) | 19 (59) |  Present | 50 (36) | 15 (47) | ||
Age | Â | Â | Â | Vessel invasion | Â | Â | Â |
  < 70 | 53 (39) | 16 (50) | 0.32 |  Absent | 61 (45) | 10 (31) | 0.23 |
  ≥ 70 | 84 (61) | 16 (50) |  Present | 76 (55) | 22 (69) | ||
Serum CEA value | Â | Â | Â | Tumor budding | Â | Â | Â |
  < 5 | 85 (62) | 21 (66) | 0.84 |  Grade 1 | 100 (73) | 6 (19) | < 0.001 |
  ≥ 5 | 52 (38) | 11 (34) |  Grade 2, 3 | 37 (27) | 26 (81) | ||
Serum CA19–9 value |  |  |  | Surgical margin |  |  |  |
  < 37 | 116 (85) | 27 (84) | 0.26 |  Negative | 133 (97) | 31 (97) | 1* |
  ≥ 37 | 21 (15) | 5 (16) |  Positive | 4 (3) | 1 (3) | ||
Tumor location | Â | Â | Â | Examined lymph node | Â | Â | |
 Right | 72 (53) | 16 (50) | 0.85 |   < 12 | 42 (31) | 12 (38) | 0.53 |
 Left | 65 (47) | 16 (50) |   ≥ 12 | 95 (69) | 20 (62) | ||
Tumor size (cm) | Â | Â | Â | Obstruction/perforation | Â | Â | |
  < 5 | 63 (46) | 18 (56) | 0.33 |  Absent | 128 (93) | 29 (91) | 0.7* |
  ≥ 5 | 74 (54) | 14 (44) |  Present | 9 (7) | 3 (9) | ||
Differentiation | Â | Â | Â | Glucose tolerance | Â | Â | Â |
 Well, moderately, pap | 121 (88) | 29 (91) | 1* |  Normal | 95 (69) | 25 (78) | 0.39 |
 Por, Muc, Sig | 16 (12) | 3 (9) |  Abnormality | 42 (31) | 7 (22) | ||
Tumor depth | Â | Â | Â | Tumor relapse | Â | Â | Â |
 pT3 | 118 (86) | 26 (81) | 0.58 |  Absent | 129 (94) | 17 (53) | < 0.001 |
 pT4 | 19 (14) | 6 (19) |  Present | 8 (6) | 15 (47) | ||